- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Halometasone cream and fractional CO2 combo effective against eczema
A recent study suggest that the combination of fractional CO2 laser treatment with halometasone cream is more effective in managing moderate-to-severe chronic hand eczema (CHE) compared to halometasone cream alone. The team led by Gongfeng Tang published the findings in Dermatology and Therapy.
The trial enrolled 67 patients with moderate-to-severe CHE and randomly assigned them to two groups. Group A (n = 33) received fractional CO2 laser treatment once every 4 weeks for 1–2 sessions, along with halometasone cream twice daily for 8 weeks. On the other hand, group B (n = 34) received halometasone cream alone, also twice daily for 8 weeks.
The primary objective of the study was to determine the proportion of patients achieving treatment success by week 12 in each group. The secondary endpoints included assessing changes in the hand eczema severity index (HECSI), patient global assessment (PaGA), dermatology life quality index (DLQI), and quality of life in hand eczema questionnaire (QOLHEQ) from baseline to week 12. Additionally, relapse rates and adverse effects were monitored.
Out of the initial participants, 29 patients in each group completed the trial. The results at week 12 demonstrated a treatment success rate of 62.1% (18/29) in group A compared to 27.6% (8/29) in group B (p = 0.009), clearly favoring the combination therapy.
Furthermore, both groups showed improvements in HECSI, PaGA, DLQI, and QOLHEQ scores compared to baseline (p < 0.05). However, the reduction in HECSI, DLQI, and QOLHEQ scores was significantly higher in group A compared to group B (p = 0.014, 0.010, and 0.014, respectively). Notably, there was no significant difference in the change of PaGA between the two groups (1.0 versus 3.0, p = 0.419).
Moreover, relapse rates were assessed at week 24 among patients who achieved treatment success. The data showed that only 11.1% (2/18) of patients in group A experienced a relapse, while a significantly higher relapse rate of 50.0% (4/8) was observed in group B (p = 0.011). Adverse effects were generally minimal, with skin pigmentation being the most common side effect reported.
Source:
Tang, G., Chang, Y., Wu, H., Liang, X., Liu, Y., & Zhuo, F. (2023). Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial. In Dermatology and Therapy. Springer Science and Business Media LLC. https://doi.org/10.1007/s13555-023-00944-w
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751